Leerink Partnrs Decreases Earnings Estimates for Nanobiotix

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Analysts at Leerink Partnrs cut their FY2026 earnings per share estimates for shares of Nanobiotix in a note issued to investors on Monday, November 24th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of $2.32 for the year, down from their prior estimate of $2.36. The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research report on Tuesday. Finally, Wall Street Zen upgraded Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $11.00.

Nanobiotix Stock Down 4.0%

Nanobiotix stock opened at $20.38 on Wednesday. The business’s 50-day moving average price is $20.55 and its 200 day moving average price is $11.21. Nanobiotix has a 52 week low of $2.76 and a 52 week high of $30.35.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.